MEDINET's cumulative third-quarter revenue for the fiscal year ending September 2026 was ¥600 million, up 6.5% year on year, while the operating loss narrowed to ¥900 million. The full-year net loss is expected to be approximately ¥1.5 billion. The completion of the CDMO technology transfer and cost reductions contributed to the results.
According to the earnings report for the cumulative third quarter of the fiscal year ending September 2026, revenue was ¥600 million, up 6.5% year on year, and the operating loss was ¥900 million. The operating loss in the same period of the previous year was ¥1.1 billion.
The technology transfer for the CDMO business was completed and related revenue was recognized, while efforts to reduce costs and control expenses continued. These factors are expected to improve profitability.
In terms of recent performance trends, net income has remained negative for the past 12 quarters, and the company continues to face a situation in which monetization has not kept pace with revenue growth. Risk factors cited include fluctuations in the number of immune cell processing cases and the concentration of sales among specific business partners.
Looking ahead, progress in CDMO contract work and controls on costs and selling, general and administrative expenses are expected to be key to improving profitability. Preparations for the domestic development of MDNT-03 and capital measures have also been identified as points to watch.